Reports and Presentations

HHSC must implement contract provisions allowing an MCO to offer their members certain medically appropriate, cost-effective, evidence-based services in lieu of mental health or substance use disorder services specified in the Medicaid State Plan.

HHSC is required to submit a report on the number of training provided in Mental Health First Aid to various described entities for fiscal year 2024.

The update provides measures taken by HHSC to further the goal of ensuring access to hospital services in rural areas.

The Legislature directed HHSC to design and implement an acute care and long tern services and supports system for individuals with an intellectual and developmental disability (IDD).

As required by Section 32.046, Texas Health and Safety Code, this report contains the fiscal year 2024 update on a five-year strategic plan to improve access to maternal depression screening, referral, treatment, and support services.

HHSC will provide an update on Mental Health Needs of High Acuity, System-Involved Children.

A legislative report is annually submitted by the PANS Advisory Council to the Legislature and Governor for recommendations on education, diagnosis and outreach concerning pediatric acute-onset neuropsychiatric syndrome.

The report fulfills the requirements of Texas Human Resources Code (HRC) Section 42.0412(e), which requires the Health and Human Services Commission (HHSC) to provide an annual report to the legislature that includes specific data concerning licensed day care centers.

The Texas Health and Human Services Commission (HHSC) in collaboration with the Department of Family and Protective Services (DFPS) and using existing resources, are to collect, compile, and publish on HHSC's website certain data aggregated on reported incidents in licensed day-care centers that threatened or impaired the basic health, safety, or welfare of a child.

The annual Kidney Health Care Program Report provides a description of benefits to eligible clients with end-stage renal disease and a discussion of expenditures and drug manufacturers rebates in fiscal year 2024.